ContractMarizyme, Inc. • October 4th, 2023 • Pharmaceutical preparations
THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
Marizyme, Inc. Jupiter, Florida 33458Letter Agreement • October 4th, 2023 • Marizyme, Inc. • Pharmaceutical preparations
This letter agreement (this “Letter Agreement”) confirms our recent discussions about an amendment to each Note in order to confirm and clarify the intent of the parties with respect to the convertibility of the Mandatory Default Amount (as defined in each Note) and certain related matters. Univest Securities, LLC, as Unitholder Representative for the Investors pursuant to Section 11.16 of each Unit Purchase Agreement, confirms that it has the authority to agree to the following amendment to each Note on behalf of each Investor pursuant to Section 11.16.
